Abstract
Treatment of chronic venous disease is a fascinating and rewarding undertaking. Once the truncal reflux is addressed, several options are available that can be used to treat the associated ulcers, varicosities, reticular veins, and telangiectasias. This review will focus on two widely employed procedures: ambulatory phlebectomy and sclerotherapy.
Keywords: phlebectomy, microphlebectomy, ambulatory phlebectomy, sclerotherapy, varicose veins, telangiectasias, interventional radiology
Phlebectomy is an historic yet well-validated treatment of superficial venous disease in the form of varicose veins that has been described in the medical literature since the time of Hippocrates (460–377 BC). 1 Techniques have evolved since that time, notably in the mid-20th century with the work of Swiss phlebologist Dr. Robert Muller and his technique utilizing hook dissectors and multiple small (stab) skin incisions. He is credited with bringing ambulatory phlebectomy into the modern form we know today. 1 2 In the more recent past, modifications have been made to improve efficacy, outcomes, and patient experience.
Today, ambulatory phlebectomy is a method whereby enlarged superficial varicose veins are removed with specialized hooks and clamps via multiple small “stab” incisions. The procedure is typically performed on an outpatient basis with local anesthetic and minimal sedation, frequently in conjunction with axial vein ablation, and is also known as stab phlebectomy, microphlebectomy, and microextraction. 3
Ambulatory phlebectomy is distinct from the other dominant form of phlebectomy, transilluminated powered phlebectomy. The trademark system for this type of phlebectomy is the TriVex system. TIPP facilitates removal of varicose veins via a combination of transillumination for vein visualization, tumescent anesthesia, and a rotating suction cannula encased in an outer stationary dissection sheath which suctions, morselizes, and removes the diseased vein. Benefits of TIPP with the TriVex system over traditional ambulatory phlebectomy include direct visualization of the target veins, decreased total number of incisions, and increased efficiency. Disadvantages include the requirement for increased anesthesia (general, nerve block, or epidural), increased bruising, and higher rate of saphenous nerve injury compared with ambulatory phlebectomy. 4
History of Phlebectomy
Hippocrates is credited with the first conceptualization of phlebectomy around 400 BC. However, the first recorded phlebectomy procedure was performed by Aulus Cornelius Celsus (56 BC to 40 AD) in which he used “exposure followed by avulsion with a blunt hook or by the touch of the cautery.” 1 2 3 Unfortunately, the ancient methods for phlebectomy were not passed along from this period, as many of the writings of Celsus were lost or destroyed.
A method very similar to that of Hippocrates and Celsus was developed in the mid-20th century when the Swiss dermatology-trained phlebologist Dr. Robert Muller became frustrated with his poor results and high rates of recurrence with large vein sclerotherapy and developed his technique. He described the use of small hooks made from broken hemostats to remove veins via small holes. His insight was attempting to remove the veins without first treating them with sclerotherapy so that they would not become “too fragile and quite difficult to be completely removed without tearing them.” He had initially perceived his developments as “original and revolutionary,” but later discovered the descriptions of a very similar procedure from some 2,000 years prior. He preferred not to have his name attached to the technique out of deference to his ancient predecessors. The technique was slow to gain traction in the medical community, however, and Dr. Muller endured a remarkable degree of criticism and hostility from the established scientific community. His dedication to teaching and his craft are to be credited for the eventual adoption and widespread dissemination of ambulatory phlebectomy. 5 6
Since that time, a variety of modifications have occurred including the development of several specialized phlebectomy hooks, tumescent anesthesia with automated injection devices, as well as adjunctive therapies for the treatment of axial reflux in the saphenous vein and tributaries. While the procedure has evolved, it has also remained quite similar even to the first descriptions of phlebectomy in ancient texts.
Varicose and reticular veins most commonly occur as sequelae of underlying venous insufficiency. The exact pathophysiologic mechanisms that lead to the development of varicose and reticular veins are not completely understood, but they most often arise in the setting of chronic venous disease (CVD) caused by reflux and/or venous obstruction. Superficial varicose veins are known to contain vein wall abnormalities including increased collagen and decreased smooth muscle/elastin. These abnormalities result in weakness and dilation of the veins and valve rings, which then gives rise to incompetence of the valve system and reflux. As in many cases, when this is combined with insufficiency and valvular incompetence of the larger superficial veins (saphenous and tributaries), venous hypertension, particularly when upright or ambulatory, develops. Increased hydrostatic pressure then exacerbates venous dilation, valvular incompetence, and reflux and the cycle continues. 1 7 This mechanistic understanding of superficial venous disease provides the rationale for treatment approaches in ambulatory phlebectomy.
Indications
Patient evaluation is critical in the workup of venous disease, because not only symptoms and findings will drive management decisions but also many symptoms of venous disease can mimic those of other disease processes. A thorough history including that of venous thrombosis/thromboembolism, prior venous intervention, edema, and family history of venous disease should be obtained. Patients can be screened in the office with bedside Doppler ultrasound to determine if axial reflux is present; however, this should be done in addition to, and not as a substitute for, formal venous Doppler evaluation. 3 Symptoms of venous CVD and varicose veins include swelling, limb heaviness, fatigue, restlessness, aching/throbbing sensation, burning, tingling, tenderness, pruritus, and cramping. As expected, symptoms are worse at the end of the day and/or after prolonged periods of standing and are relieved with leg elevation. Exam findings range from spider veins and telangiectasias to varicosities to ulceration in the extreme cases. The primary varicose vein classification system used by practitioners is the CEAP (clinical, etiology, anatomy, pathophysiology) score. 1 8 9 10 11 Several adjunctive scoring systems and questionnaires have also be been developed including the Venous Clinical Severity Score (VCSS), Venous Segmental Disease Score (VSDS), Venous Disability Score (VDS), the Aberdeen Varicose Veins Questionnaire (AVVQ), and the Chronic Venous Insufficiency Questionnaire (CIVIQ). These are sometimes used in the clinical evaluation and each provides varying degrees of additional clinical, anatomical, and quality-of-life information. 1 8 9 The decision on the treatment for varicose and reticular veins can be made independent of intention to treat axial reflux (such as via ablation), and in some cases symptoms from varicose veins may exist without the presence of axial reflux in larger veins. In practice, specific treatments are based largely on physician and patient preference in conjunction with symptomatology. Entities that can be treated with ambulatory phlebectomy include asymptomatic varicose and reticular veins, symptomatic reticular and varicose veins, and complications of varicose veins. 2 Additionally, the decision of when to treat often requires consideration of the patient's insurance status, as many insurers require a course of compression therapy before qualification for the reimbursement of procedural therapies.
Contraindications
There are few absolute contraindications to ambulatory phlebectomy. The Society of Interventional Radiology (SIR) lists pelvic and extremity venous interventions as a “low bleeding risk” procedure, in which preoperative coagulation laboratories are not routinely recommended and thresholds of international normalized ratio (INR) ≤3.0 and platelets >20 × 10 9 /L are recommended. 12 Contraindications that have been cited include infectious dermatitis, cellulitis in surrounding areas, severe peripheral edema, and seriously ill or hospitalized patients. 2
Ambulatory phlebectomy is often performed concurrently with the treatment for axial reflux, most commonly at the time of saphenous vein ablation via endovenous laser therapy (EVLT) or endovenous thermal ablation. There has been debate as to whether the two procedures should be performed in the same visit or in a staged fashion. The dominant rationale for staged approach is based on the fact that axial vein ablation alone is sufficient for the treatment of reflux and superficial varicosities in a minority of patients, and therefore, follow-up phlebectomy should be reserved only for those patients who are unsatisfied or insufficiently treated. In our review of the more recent literature, the number of patients requiring a second procedure for the treatment of their varicosities ranges from 30 to 60%. 13 The majority of recommendations are now for combined ablation with phlebectomy. A 2016 review evaluated 8 comparative studies, including three prospective randomized (PR) trials. Final recommendations from 5 of the 8 studies, including all three PR trials were for simultaneous ablation for axial reflux and phlebectomy in one setting, citing superior early (6 weeks) Aberdeen Varicose Vein Questionnaire (AVVQ) scores and Venous Clinical Severity Score (VCSS). In the largest of the prospective trials (101 patients), superiority in AVVQ persisted at 12 months. 11 13 14 15 Interestingly, the overwhelming majority of patients who refused to participate in the trial (95%) did so to avoid potential randomization to the staged arm, citing desire for single-setting treatment as the reason. 13 The largest retrospective analysis from 2015 included 580 limbs treated with radiofrequency ablation (RFA) with or without TIPP and found greater improvement in VCSS with simultaneous therapy versus RFA alone. These authors also reported a statistically significant increase in minor complications with combined therapy, reporting slight increase in frequency of hematomas and asymptomatic superficial thrombophlebitis. It should be emphasized that this study utilized TIPP as the phlebectomy technique, which is not the focus of discussion herein. 16
While some debate may persist, the data are accumulating to support axial ablation combined with superficial phlebectomy in a single setting. This is the method of choice at the authors' home institution, and we find it to be preferred in the majority of patients when the option of combined versus staged approach is presented.
Technique
Prior to the procedure, the varicosities to be targeted are marked with the patient standing, as they will be much less obvious when the patient is supine. The patient should be positioned such that the ambient lighting falls tangentially over the leg, to create shadows accentuating the vein contours, facilitating easier identification of the varicosities in the targeted distribution. Palpation is often used as an adjunct to identify varicosities that are less obvious. The patient should also be asked to identify veins that are troublesome, as this may facilitate visualization of veins that were initially not appreciated.
Once the axial reflux has been treated, attention is turned to phlebectomy. Local anesthesia is achieved using the same equipment that was used for tumescent anesthesia for the saphenous ablation. At our institution, we use a 25-g spinal needle and inject a dilute lidocaine tumescent created by adding 100 mL of 2% lidocaine to 900 mL of lactated ringers. Injection is facilitated by a pump activated by foot switch. Using the skin markings as a guide, a small incision is made over the varicosity, using a 5.0-mm 15-degree Beaver blade (Beaver-Visitec International, Waltham, MA), and a vein hook is used to capture a vein and bring it through the incision ( Fig. 1a ). Each incision should be made in parallel to the skin lines of the region to minimize scar formation.
Fig. 1.

Phlebectomy. ( a ) A “pearly white” varicosity is successfully engaged with an Oesch-style hook and is about to be clamped with curved hemostats. ( b ) The varicosity has been captured with hemostats and pulled out through the incision. The Varady spatula-shaped extractor better delineates the proximal and distal components of vein. ( c ) The Varady extractor is used to clearly define the vein heading in two directions. ( d ) Proximal and distal components of the vein captured with hemostats. These could be both simply be retracted and removed. Alternatively, they can be used to harvest longer segments of vein. ( e ) The vein is captured at a more distal site with an Oesch-style vein hook. Gentle tension reveals the path of the vein which can be easily palpated. ( f ) The process continues with the vein captured at a third station, allowing a relatively long, 8-cm segment of vein to be harvested.
A variety of vein hook shapes are available from a variety of manufacturers, and the tool of choice is entirely operator dependent. Our most frequently used hook is an “Oesch-style” hook, as it provides the highest success rate in our clinic. Other useful shapes include the “crochet” hooks which are often used for small varicosities and Varady double-ended extractors, which have a blunt hook on one end and a very useful spatula on the other. This spatula can be used to gently probe the “knuckle” of the exposed vein so that it can be captured at two points, potentially allowing the phlebectomy to be performed proximally and distally along the length of the targeted vein ( Fig. 1 ). It should be noted that there is often tactile feedback that will let the operator know a vein has been hooked, as the vein will often feel “rubbery” and provide a degree of tension that other subcutaneous tissues will not. This is immediately felt by the operator, but skilled assistants will often see the subtle visual difference between securing a vein and not securing a vein. The other clue that a vein has been harvested is the “pearly white” appearance of a varicosity ( Fig. 1a ). Once the vein has been successfully captured, it is gently brought up out of the incision, allowing it to be clamped with a hemostat ( Fig. 1b ). Care should be taken to avoid inadvertently clamping the skin with the vein. Tissue that yields a firm resistance is not a vein, and this pass should be abandoned. A thin, string-like structure may very well be a small sensory nerve, and therefore should be gently returned to the incision.
Paying attention to the tactile feedback is key for successful phlebectomy. The Oesch-style hooks are designed to allow a smooth, gentle approach using a pronate-to-supinate hand motion that will allow the hook to set into the vein. One should not employ abrupt, tearing motions that diminish accurate tactile feedback. Making passes with the hook in various directions and at various depths may increase the chances of success. If one hook does not bring success, consider using another type of hook. Remember that gravity may move a vein to a more dependent position with the patient supine. In addition, as confidence builds, if only the edge of the vein is captured, one can release it and attempt to capture a more substantial portion of the vein, thereby avoiding tearing the vein and losing it. If there is no success at one incision after several attempts, abandon it for the time being, but return to it later as this often allows a successful phlebotomy at that previously unsuccessful site.
After the phlebectomy is completed, the leg is cleaned, and Steri-Strips are used to close the incisions. A 4 × 4 gauze can be used to dress the incisions and augment the compression provided by donning 20 to 30 mm Hg compression stockings that are either thigh high or panty hose style. At our clinic, we recommend 48 hours of continued compression, then 6 weeks of compression during the day while awake. Follow-up is at 1 week, to assess the patient's progress and check patency of the saphenofemoral junction, and again at 6 weeks for formal ultrasound closure study to assess the closure of the treated vein(s).
Sclerotherapy
Indications
Sclerotherapy can be used across a wide spectrum of venous disease, including saphenous reflux, varicose tributaries of various calibers, bleeding varicosities, pathologic perforators, vascular malformations, pelvic congestion, and unsightly reticular veins and telangiectasias. 17 18 Of note, facial telangiectasias can be treated, but are less responsive to those on the lower extremities, likely secondary to a greater arteriolar component in this anatomic region and the inability to easily compress the lesion after treatment. 19
Contraindications
Relative contraindications include marked allergic diathesis/severe bronchial asthma, poor performance status with significant comorbidities, immobility, hypercoagulable state, known asymptomatic patent foramen ovale (PFO), leg edema, and very large varices. 18
Absolute contraindications include known allergy to the sclerosant, history of extensive DVT, acute superficial or deep vein thrombosis, local infection in the area of anticipated sclerotherapy, systemic infection, pregnancy, advanced peripheral arterial disease, and advanced collagen vascular disease. 18 20
Commonly Used Sclerosants
Agents that are used for sclerotherapy are categorized as osmotic agents, chemical irritants, and detergents. The sclerosants most commonly used in the United States include hypertonic saline, an osmotic agent, and two detergents—polidocanol and sodium tetradecyl sulfate (STS). 17 18 21 In addition to these three, glycerin and sodium morrhuate are used commonly worldwide. 21
Historically, hypertonic saline has been used extensively, as it has a low risk of toxicity, is inexpensive, and has virtually no risk of an allergic reaction. 18 19 22 However, it has fallen out of favor because its use is associated with muscle cramping, pain, ulceration, and hyperpigmentation. 18 21 22 Of note, the Food and Drug Administration (FDA) has approved hypertonic saline as an abortifacient, but not as a sclerotherapy agent. Nonetheless, hypertonic saline enjoyed wide, off-label use in the 1970s through the 1990s. 18 22
Polidocanol was introduced as a topical and local anesthetic in the 1930s and later developed for use in sclerotherapy in the 1960s. 18 19 20 Its anesthetic properties make it less painful than other agents, and it has a low-risk profile. 20 The incidence of nonfatal allergies and anaphylaxis with polidocanol ranges from 0.01 to 0.91%. 20 While it is thought to cause less pigmentation, this may be related to inaccurate comparison of sclerosant concentration. 18 20 It is available in the United States in 0.5 and 1% solutions and was FDA approved in 2010. 17 18 It can be used as either foam or liquid, and, while volumes used clinically vary widely, the generally accepted maximum dose is 10 mL of 3% solution. 18
Sodium tetradecyl sulfate is another detergent sclerosant that has been used since the 1940s. 18 19 It was approved for use in the United States in 1946 and is commercially available in 1 and 3% solution. 20 Nonfatal allergic reactions and anaphylactic shock are rare, with an estimated incidence of 0.3%. It is thought to be approximately three times stronger than polidocanol, and, as a result, is diluted with normal saline to a level appropriate for the diameter vein being treated, frequently to 0.25 to 0.5%. Maximum clinical dose again varies widely by author, but the maximum recommended dose is 10 mL of 3% solution. 18 20
Specific Diseases Treated with Sclerotherapy
Varicose Veins
Sclerotherapy for varicose veins was described in the 1800s, but the agents used resulted in significant morbidity and mortality. 19 Physicians continued to search for better sclerosants, but it was not until the introduction of sodium morrhuate in 1930 and STS in 1946 that the risk:benefit ratio allowed the procedure to become more widespread. 19 As surgical techniques improved for the treatment of varicose veins, they eclipsed sclerotherapy for an extended period. However, in the 1990s, with the development of the detergent sclerosants being used to create foam to treat varicose veins and truncal reflux, 17 23 this modality enjoyed a resurgence which has continued until today.
Reticular Veins and Telangiectasias
Sclerotherapy for telangiectasias was first described in the 1930s. 19 22 24 Prior to this, an interesting array of procedures were employed in an attempt to deal with these unsightly lesions, including cautery, linear scarification, radium therapy, and electrodesiccation. 24 Subsequently, in 1934, Biegeleisen described his search for a safe and effective agent for sclerotherapy, and eventually settled on sodium morrhuate, although he advised caution because of the risk of significant necrosis if injected perivascularly. 24 He recommended using proper lighting, good magnification, and the “thinnest and finest attainable” needles, 24 advice that holds true today.
Technique
All patients should undergo a targeted history and physical examination, as well as an appropriate vascular ultrasound evaluation when indicated. Patients with large varicose veins and symptoms suggesting chronic venous insufficiency should be evaluated for underlying axial reflux. Photographs are taken before treatment is initiated and entered into the electronic medical record.
After informed consent is obtained and potential adverse events reviewed, the approach is to treat the largest veins first. Any varicose veins that are to be treated are identified. The patient should be in a comfortable position and excellent lighting should be available. We routinely use ultrasound to confirm needle position within the varicosity and to follow the foam as it progresses centrally. For small varicosities, 1 mL of 0.5% STS is mixed with 3 mL of air and agitated with two syringes connected by a three-way stopcock. A 27-gauge × ½-inch butterfly needle is used to access the varicosity or reticular vein, and the foam is slowly injected, watching it travel proximally ( Fig. 2 ). Higher concentrations and slightly larger volumes may be needed for larger varicosities. At our institution, in cases that involve truncal reflux, sclerotherapy of varicosities is typically done in a separate session, as EVLT will have been used to treat the underlying reflux. However, in practices where the truncal reflux is treated with ultrasound-guided foam sclerotherapy, treatment of associated varicosities can take place in the same setting.
Fig. 2.

Telangiectasia sclerotherapy: ( a ) A 30-gauge needle, slightly bent, allows a flat, tangential approach to the very superficial telangiectasia. Note traction by the non-dominant hand, providing tension on the skin and allowing easier access to the targeted vessel. ( b ) Gently pressure allows injection of the 0.25% STS to displace blood and start to fill the minute spider vein.
Reticular veins measuring 2 to 4 mm in diameter and superficial venulectasias can be similarly treated with a 27-gauge butterfly needle, but the STS will be diluted to 0.25 to 0.5% and then used to create foam as described earlier ( Fig. 3 ). The needle will be bent slightly to allow an optimal approach angle and to keep the bevel up. At times, a vein light may be needed for better visualization of the reticular veins. Countertraction using one's nondominant hand is key for success. The injection should not be forced, but should be slow and smooth if the needle tip is intravascular. Gently massage of the treated vessel with an alcohol pad or alcohol-soaked cotton ball will facilitate passage of the sclerosant to adjacent, communicating vessels.
Fig. 3.

Foam sclerotherapy of a larger venulectasia. ( a ) A 27-gauge butterfly needle is used. Again, the needle is slightly bent to allow a low, flat approach to the vessel. ( b ) The STS foam is gently injected, displacing blood, and then massaged to fill more proximal components. ( c ) Following injection, the treated vessel has a reddish appearance.
For telangiectasias, good lighting and magnification with binocular loupes greatly facilitate successful access of the small vessels. These lesions are treated with either 0.25 to 0.5% polidocanol or 0.1 to 0.25% STS which is delivered via a 30-gauge × ½-inch needle that is bent slightly to allow a very flat, tangential approach to the target. The spider veins are very superficial and tactile feedback is important. Typically, the blood is temporarily displaced by the injected sclerosant. Injections should not be forced, and creation of wheals should be avoided to decrease the risk of hyperpigmentation, matting, and ulcer formation.
Following treatment of telangiectasias and reticular veins, cotton balls are secured over the areas treated with paper tape and the patient is assisted with donning 20 to 30 mm Hg thigh-high compression stockings while still on the procedure table. Similarly, compression stockings are applied following treatment of varicose veins. The duration of compression following sclerotherapy varies greatly, but 3 to 7 days following treatment of telangiectasias and reticular veins has been shown to decrease hyperpigmentation and improve outcomes. 18 Longer durations should be considered when larger varicosities have been treated. Individual patient results may vary, and repeat sclerotherapy may be required, underscoring the importance of setting patients' expectations.
Adverse Events
Hyperpigmentation occurs commonly following sclerotherapy, peaking at 6 to 8 weeks posttreatment and occurring in 10 to 30% of patients. 21 However, it spontaneously resolves in 70% of patients at 6 months and 99% of patients at 1 year. 17 21 In addition, the risk of this complication can be reduced by using the lowest concentration of sclerosant and the smallest volume necessary. 18 This topic warrants setting patient expectations and being clear that, while common, hyperpigmentation will usually resolve over time.
The more serious concerns are reports of neurological events and visual disturbances after sclerotherapy. 21 There have been 16 reported cases of transient ischemic attack or stroke, 21 with transient visual disturbances occurring in 0.09 to 2% of cases. 17 25 While these events are rare, this concern has resulted in the development of proprietary endovenous microfoam (PEM) which has been shown to be more stable and have smaller gas bubbles than physician compounded foam, thereby having fewer neurologic complications. 17 26 In addition, the use of various gas mixtures, including CO 2 , O 2 , and CO 2 /O 2 mixture, reduce the risk of neurologic and visual events. 17 Since the cost of PEM and various gases may be prohibitive for many practices, the safe practices of using a test dose to see how the patient responds to sclerotherapy, using small volumes of sclerosant, using foam with no grossly visible bubbles and avoiding foam sclerotherapy in patients with a history of a PFO are recommended. 17 18
Other potential adverse events include deep venous thrombosis, thrombophlebitis, and cellulitis. Following treatment of telangiectasias, “matting” or neovascularization can be seen. 18 In addition, trapped coagulum following sclerotherapy of reticular veins and telangiectasia can be treated by releasing the retained material with a small caliber needle or an 11 number blade. This will lessen any discomfort and diminish the chance of hyperpigmentation.
Conclusions
Ambulatory phlebectomy and sclerotherapy both have evolved over the years and have now matured to a point that they can be performed safely and effectively in the outpatient setting. While the use of these various therapies is largely influenced by a physician's training and local practice patterns, it is hoped that this review has broadened the reader's horizons a bit, allowing one to incorporate all of these into a useful armamentarium.
Footnotes
Conflict of Interest None declared.
References
- 1.ESVS Guidelines Committee . Wittens C, Davies A H, Bækgaard N. Editor's choice - management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS) Eur J Vasc Endovasc Surg. 2015;49(06):678–737. doi: 10.1016/j.ejvs.2015.02.007. [DOI] [PubMed] [Google Scholar]
- 2.Kabnick L S, Ombrellino M. Ambulatory phlebectomy. Semin Intervent Radiol. 2005;22(03):218–224. doi: 10.1055/s-2005-921955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Geersen D F, Shortell C EK. Phlebectomy techniques for varicose veins. Surg Clin North Am. 2018;98(02):401–414. doi: 10.1016/j.suc.2017.11.008. [DOI] [PubMed] [Google Scholar]
- 4.Cheshire N, Elias S M, Keagy B. Powered phlebectomy (TriVex) in treatment of varicose veins. Ann Vasc Surg. 2002;16(04):488–494. doi: 10.1007/s10016-001-0100-1. [DOI] [PubMed] [Google Scholar]
- 5.Muller R. Interview with Dr. Robert Muller. Father of modern day ambulatory phlebectomy. Interview by Jose A. Olivencia. Dermatol Surg. 1998;24(10):1147–1150. doi: 10.1111/j.1524-4725.1998.tb04088.x. [DOI] [PubMed] [Google Scholar]
- 6.Muller R. [Treatment of varicose veins by ambulatory phlebectomy] Phlebologie. 1966;19(04):277–279. [PubMed] [Google Scholar]
- 7.Eberhardt R T, Raffetto J D. Chronic venous insufficiency. Circulation. 2014;130(04):333–346. doi: 10.1161/CIRCULATIONAHA.113.006898. [DOI] [PubMed] [Google Scholar]
- 8.Hamdan A. Management of varicose veins and venous insufficiency. JAMA. 2012;308(24):2612–2621. doi: 10.1001/jama.2012.111352. [DOI] [PubMed] [Google Scholar]
- 9.Zolotukhin I A, Seliverstov E I, Zakharova E A, Kirienko A I. Short-term results of isolated phlebectomy with preservation of incompetent great saphenous vein (ASVAL procedure) in primary varicose veins disease. Phlebology. 2017;32(09):601–607. doi: 10.1177/0268355516674415. [DOI] [PubMed] [Google Scholar]
- 10.Mauro M A, Murphy K P, Thomson K R, Venbrux A C. 3rd ed. St. Louis, MO: Saunders; 2020. Image-Guided Interventions: Expert Radiology Series; pp. 619–624. [Google Scholar]
- 11.Lane T RA, Kelleher D, Shepherd A C, Franklin I J, Davies A H. Ambulatory varicosity avulsion later or synchronized (AVULS): a randomized clinical trial. Ann Surg. 2015;261(04):654–661. doi: 10.1097/SLA.0000000000000790. [DOI] [PubMed] [Google Scholar]
- 12.Patel I J, Rahim S, Davidson J C. Society of Interventional Radiology Consensus Guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions—Part II: Recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019;30(08):1168–11840. doi: 10.1016/j.jvir.2019.04.017. [DOI] [PubMed] [Google Scholar]
- 13.Hager E S, Ozvath K J, Dillavou E D. Evidence summary of combined saphenous ablation and treatment of varicosities versus staged phlebectomy. J Vasc Surg Venous Lymphat Disord. 2017;5(01):134–137. doi: 10.1016/j.jvsv.2016.07.009. [DOI] [PubMed] [Google Scholar]
- 14.Carradice D, Mekako A I, Hatfield J, Chetter I C. Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. Br J Surg. 2009;96(04):369–375. doi: 10.1002/bjs.6556. [DOI] [PubMed] [Google Scholar]
- 15.Theivacumar N S, Dellagrammaticas D, Mavor A ID, Gough M J. Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above- and below-knee reflux? A randomized controlled trial. J Vasc Surg. 2008;48(01):173–178. doi: 10.1016/j.jvs.2008.01.062. [DOI] [PubMed] [Google Scholar]
- 16.Michigan Vein Health Program . Obi A T, Reames B N, Rook T J. Outcomes associated with ablation compared to combined ablation and transilluminated powered phlebectomy in the treatment of venous varicosities. Phlebology. 2016;31(09):618–624. doi: 10.1177/0268355515604257. [DOI] [PubMed] [Google Scholar]
- 17.Gibson K, Gunderson K. Liquid and foam sclerotherapy for spider and varicose veins. Surg Clin North Am. 2018;98(02):415–429. doi: 10.1016/j.suc.2017.11.010. [DOI] [PubMed] [Google Scholar]
- 18.Mann M W.Sclerotherapy: it is back and better Clin Plast Surg 20113803475–487., vii [DOI] [PubMed] [Google Scholar]
- 19.Goldman M P, Bennett R G.Treatment of telangiectasia: a review J Am Acad Dermatol 198717(2, Pt 1):167–182. [DOI] [PubMed] [Google Scholar]
- 20.Duffy D M. Sclerosants: a comparative review. Dermatol Surg. 2010;36 02:1010–1025. doi: 10.1111/j.1524-4725.2009.01469.x. [DOI] [PubMed] [Google Scholar]
- 21.Yiannakopoulou E.Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins Pharmacology 201698(1-2):62–69. [DOI] [PubMed] [Google Scholar]
- 22.Watson J J, Mansour M A. Cosmetic sclerotherapy. J Vasc Surg Venous Lymphat Disord. 2017;5(03):437–445. doi: 10.1016/j.jvsv.2017.02.002. [DOI] [PubMed] [Google Scholar]
- 23.Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg. 2001;27(01):58–60. [PubMed] [Google Scholar]
- 24.Biegeleisen H I. Telangiectasia associated with varicose veins. JAMA. 1934;102(25):2092. [Google Scholar]
- 25.Willenberg T, Smith P C, Shepherd A, Davies A H. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Phlebology. 2013;28(03):123–131. doi: 10.1258/phleb.2012.012051. [DOI] [PubMed] [Google Scholar]
- 26.VANISH-2 Investigator Group . Todd K L, III, Wright D I. Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2) J Vasc Surg Venous Lymphat Disord. 2015;3(03):258–2640. doi: 10.1016/j.jvsv.2015.03.003. [DOI] [PubMed] [Google Scholar]
